NYSE:ELANPharmaceuticals
Why Elanco (ELAN) Is Down 8.2% After Guiding Higher 2026 Revenue Despite Ongoing Net Losses
Elanco Animal Health reported past fourth quarter 2025 sales of US$1,144 million and full-year 2025 sales of US$4,715 million, alongside a net loss of US$276 million for the quarter and US$232 million for the year.
Despite these losses, Elanco issued revenue guidance for 2026 of US$1,280 million to US$1,305 million for the first quarter and US$4,950 million to US$5,020 million for the full year, highlighting expected 4% to 6% growth that has underpinned continued analyst confidence in its...